Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + trebananib
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The combination of temsirolimus and trebananib is an investigational drug combination that has been studied in clinical trials for advanced solid tumors. This combination targets both the ANG-Tie2 pathway (via trebananib) and the mTOR pathway (via temsirolimus). Trebananib (also known as AMG 386) is an inhibitor of ANG1/2-Tie2 interaction that may stop tumor growth by blocking blood flow to tumors. Temsirolimus is an mTOR inhibitor that may stop the growth of tumor cells by blocking certain cellular pathways involved in cancer cell proliferation. Combination therapy of temsirolimus and trebananib (AMG 386). Trebananib is an inhibitor of ANG1/2-Tie2 interaction that may inhibit tumor growth by blocking blood flow to tumors. Temsirolimus is an mTOR inhibitor that may stop the growth of tumor cells by blocking the PI3K/Akt/mTOR pathway. The combination was investigated based on evidence of crosstalk between the ANG-Tie2 and PI3K/Akt/mTOR pathways, with the hypothesis that combined blockade may have additive anti-cancer activity.
- Other names
- trebananib + temsirolimusTr + T
02
Targets
ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)TEK (Tie2)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on temsirolimus + trebananib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + trebananib.